Ludovic Bigot

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Engineering microcavity arrays as a niche for high-throughput and high-content analysis of tumoroids: A detailed methodology.

Engineering microcavity arrays as a niche for high-throughput and high-content analysis of tumoroids: A detailed methodology.

Journal: Methods in cell biology

Published: March 30, 2026

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.

Journal: NPJ precision oncology

Published: February 13, 2026

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 15, 2025

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.

Journal: Cancer research

Published: May 13, 2025

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Journal: Nature communications

Published: December 04, 2024

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.

Journal: Molecular cancer

Published: July 08, 2024

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 11, 2024

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Journal: Cancer discovery

Published: February 17, 2024

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 23, 2023

Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.

Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.

Journal: European urology oncology

Published: July 21, 2023

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

Journal: Cancer discovery

Published: December 23, 2022

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors.

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 06, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026